Search

Search Constraints

You searched for: Author/Creator Pataer, Apar

Search Results

1. 277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. (9th November 2020)

2. 277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. (9th November 2020)

5. Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Issue 1 (6th June 2018)

6. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. (October 2018)

7. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Issue 1 (1st February 2015)

8. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Issue 1 (1st February 2015)

10. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. (30th August 2020)